Joint Research, Development, Option and License Agreement Sample Contracts
JOINT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENTJoint Research, Development, Option and License Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England
Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.
AMENDMENT N°. 9Joint Research, Development, Option and License Agreement • April 30th, 2025 • Innate Pharma SA • Biological products, (no disgnostic substances)
This Amendment No. 9 (the “Amendment”) is made and entered into as of July 18th 2024 (“Effective Date”) between Innate Pharma SA, a corporation existing under the laws of France (“IPH”) and Novo Nordisk A/S, a corporation existing under the laws of Denmark (“NN”) with regards to the Joint Research, Development, Option and License Agreement dated March 28, 2006, as amended by Amendment and Supplement No.1, dated October 8, 2008, Amendment and Supplement No. 2, dated October 8, 2008, Amendment and Supplement No. 3, dated June 26, 2009, Amendment No. 4, dated December 13, 2010, Amendment No. 5, dated December 13, 2010, Amendment 6 dated July 1st 2011, Amendment and Supplement No. 7 dated February 5, 2014 and Amendment and Supplement No. 8 dated September 16 2016 (collectively, the “Agreement”). NN and IPH may each individually be referred to as “Party” and collectively as “Parties”.